Eli Lilly has denied the assertions of a recent New York Times article alleging that incoming CEO John Lechleiter encouraged off-label promotion of the company's embattled schizophrenia treatment Zyprexa (olanzapine) in an e-mail he sent in 2003.

Endo Pharmaceuticals announced that David Holveck has been named president, CEO and a director of the company, effective April 1, 2008.

Endo Pharmaceuticals has entered into a licensing agreement with Novartis to obtain the exclusive US marketing rights for the prescription medicine Voltaren Gel (diclofenac sodium topical gel) 1%.

Shire Pharmaceuticals is hitting "the road" as part of a new unbranded education campaign for patients with ulcerative colitis (UC), complete with live events in 10 cities.

Publicis Healthcare Communications Group announced the appointment of Lyn Falconio to EVP, network navigator on the AstraZeneca account.

Allergan said it has received a subpoena for documents related to the promotion of its anti-wrinkle injection Botox.

Sales reps could be effectively barred from circulating journal article reprints discussing off-label uses under FDA's draft guidance on "good reprint practices," and the agency considers the policy to be effective already, even in its draft form.

The FDA has issued draft guidance on "Good reprint practices" for distribution of journal articles involving unapproved uses of FDA-approved drugs and medical devices.

Steve Case, chairman and CEO of Revolution Health and co-founder of AOL, yesterday lamented pharma's hesitation to embrace interactive and inject a greater share of promotional budget into online initiatives.

The decision by Sepracor to in-license the US marketing rights to inhaled corticosteroid Alvesco caps a four-year commercial and regulatory odyssey for the asthma drug.